tiprankstipranks
Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC
The Fly

Unicycive Therapeutics announces U.S. FDA acceptane for NDA for OLC

Unicycive Therapeutics (UNCY) announced that the U.S. Food and Drug Administration, FDA, has accepted the New Drug Application, NDA, for Oxylanthanum Carbonate, OLC, and has set a Prescription Drug User Fee Act, PDUFA, target action date of June 28, 2025. If approved, OLC has the potential to meaningfully improve the treatment burden for hyperphosphatemia patients with chronic kidney disease, CKD, on dialysis.

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App